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Obesity is a major risk factor for inﬂammatory dermatologic diseases, including atopic dermatitis and psoriasis.
In addition, recent studies have shown that obesity impairs lymphatic function. As the lymphatic system is a
critical regulator of inﬂammatory reactions, we tested the hypothesis that obesity-induced lymphatic dysfunction
is a key regulator of cutaneous hypersensitivity reactions in obese mice. We found that obese mice have
impaired lymphatic function, characterized by leaky capillary lymphatics and decreased collecting vessel
pumping capacity. In addition, obese mice displayed heightened dermatitis responses to inﬂammatory skin
stimuli, resulting in both higher peak inﬂammation and a delayed clearance of inﬂammatory responses. Injection
of recombinant vascular endothelial growth factor-C remarkably increased lymphangiogenesis, lymphatic
function, and lymphatic endothelial cell expression of chemokine (C–C motif) ligand 21, while decreasing
inﬂammation and expression of inducible nitrous oxide synthase. These changes resulted in considerably
decreased dermatitis responses in both lean and obese mice. Taken together, our ﬁndings suggest that obesity-
induced changes in the lymphatic system result in an ampliﬁed and a prolonged inﬂammatory response.
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INTRODUCTION
It is estimated that more than one-third of US adults are
obese, with the incidence rapidly rising in adult and pediatric
populations (Ogden et al., 2014). Obesity is associated
with a wide variety of pathologies, including coronary artery
disease, insulin resistance, diabetes, and malignancy
(Garﬁnkel, 1985; Mokdad et al., 2003; Lavie et al., 2009;
Glass and Olefsky, 2012). In addition, obesity has a profound
impact on a variety of dermatologic diseases, including psori-
asis and atopic dermatitis in both children and adults (Marino
et al., 2004; Silverberg et al., 2011, 2012).
Chronic inﬂammation is a major mechanism regulating
pathological changes in obesity. For example, visceral adipose
deposition in obese individuals is associated with chronic
inﬁltration of activated T cells and macrophages. These changes
result in increased local and systemic expression of a multitude
of inﬂammatory cytokines, including tumor necrosis factor-α,
IL-6, IL-1β, chemokine (C–C motif) ligand 2 (CCL2), and others
(Gregor and Hotamisligil, 2011; Lumeng and Saltiel, 2011).
These inﬂammatory changes have crucial roles in the
development of metabolic syndrome, insulin resistance, tumor
metastasis, and cardiovascular disease (Mokdad et al., 2003;
Lavie et al., 2009; Glass and Olefsky, 2012; Perez-Hernandez
et al., 2014). Similarly, previous studies have shown that obese
patients have increased subcutaneous tissue inﬂammation, and
that these pathological changes contribute to the development
of dermatological disorders (Hamminga et al., 2006; Gerdes
et al., 2011). However, although it is clear that inﬂammation is
a key regulator of pathological outcomes in obesity, the effects
of these changes on dermatological diseases and the regulation
of inﬂammatory responses in obesity remain poorly understood.
Recent studies have shown that obesity impairs lymphatic
function both in mice and in humans (Lim et al., 2009;
Arngrim et al., 2013; Lim et al., 2013; Weitman et al., 2013;
Savetsky et al., 2014). For example, our group has reported
that obese mice have decreased ability to transport interstitial
ﬂuid via cutaneous lymphatics and have remarkably
decreased trafﬁcking of antigen-presenting cells to regional
lymph nodes (Weitman et al., 2013). Furthermore, Rutkowski
et al. (2010) demonstrated that adipose tissue accumulation
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reduces interstitial ﬂuid transport by lowering hydraulic
conductivity. Other investigators have shown that obese
mice have impaired lymphatic collecting vessel pumping
function (Blum et al., 2014). These ﬁndings are supported
by clinical studies demonstrating that obese patients have
decreased clearance of macromolecules from fat depots when
compared with normal controls, and that massively obese
patients spontaneously develop lymphedema (a condition in
which impaired lymphatic drainage function results in
chronic limb swelling) (Greene et al., 2012; Arngrim et al.,
2013). The relationship between obesity and the lymphatic
system appears to be bidirectional, as previous studies have
shown that mice with congenital lymphatic defects resulting
from Prox-1 haploinsufﬁciency go on to develop adult onset
obesity (Harvey et al., 2005). As the lymphatic system is a
critical physiologic regulator of inﬂammation and immune
responses, obesity-induced lymphatic dysfunction may act in
a feed-forward manner to amplify the pathological conse-
quences of obesity in end organs. This hypothesis is supported
by previous studies demonstrating that improving lymphatic
function with exogenous delivery of lymphangiogenic cyto-
kines, such as vascular endothelial growth factor (VEGF)-C,
decreases acute/chronic skin inﬂammation in lean mice
(Kataru et al., 2009; Huggenberger et al., 2010). Thus,
improving lymphatic function in obese patients may serve
as a means of mitigating the pathology of cutaneous disorders
associated with obesity.
In the current study, we investigated the role of the lymphatic
system in regulating dermatitis in obesity. We found that obese
mice have impaired lymphatic function and heightened
dermatitis responses to inﬂammatory skin stimuli. Obese
mice had both higher peak inﬂammation and a delayed
clearance of inﬂammatory responses. Increasing lymphatic
function by injection of recombinant human VEGF-C (rhVEGF-
C) remarkably decreased dermatitis responses in obese mice,
leading to decreased peak inﬂammation and an increased rate
of its clearance. Taken together, our ﬁndings suggest that
obesity-induced changes in the lymphatic system result in an
ampliﬁed and a prolonged inﬂammatory response in the skin.
RESULTS
Obese mice have impaired lymphatic function at baseline
As expected, feeding male C57BL/6J mice a high-fat diet
(HFD) for 10–12 weeks resulted in a signiﬁcant increase in
body weight and subcutaneous adipose deposition as
reﬂected by increased perilipin-positive cell accumulation
and ear thickness when compared with mice fed a normal
chow diet (Figure 1a–c; Po0.01 for both). Consistent with our
previous studies, immunoﬂuorescence analysis of ear skin
demonstrated signiﬁcant baseline increases in the number of
CD45+ and CD3+ cells in obese mice as compared with lean
controls (Figure 1d and e, and Supplementary Figure S1a and
b online; Po0.01 for all) (Weitman et al., 2013; Savetsky
et al., 2014). In addition, obese mice had signiﬁcantly fewer
subcutaneous lymphatic vessel endothelium hyaluronan
receptor 1 (LYVE-1)+ lymphatic vessels as compared with
controls (Figure 1d and f; Po0.01). Lymphangiography using
subdermal Evans blue dye injection demonstrated the
presence of leaky capillary lymphatics (white arrows) in
obese mice as compared with lean controls (Figure 1g; upper
panel). These ﬁndings were conﬁrmed with functional
lymphatic vessel staining using FITC ﬂuorescently conjugated
tomato lectin in whole-mounted specimens stained for α-
smooth muscle actin and LYVE-1. Obese animals had
signiﬁcantly less uptake (yellow arrows) and more extravasa-
tion of peripherally injected tomato lectin in the ear (white
arrow and outlined region) as compared with controls
(Figure 1g; lower panel). Furthermore, analysis of collecting
lymphatic pumping frequency in the hind limb and tail
demonstrated a 2- to 3-fold decrease in packet frequency
(visualized using near-infrared (NIR) imaging) in obese mice
as compared with controls (Figure 1h and Supplementary
Movies S1 online; Po0.05 and Po0.01 for the tail and hind
limb, respectively). Finally, consistent with our observation
that obese mice have impaired lymphatic function, we found
that obese mice had signiﬁcantly decreased systemic uptake
of peripherally injected macromolecules (FITC–dextran) as
compared with controls (Supplementary Figure S2b online;
Po0.05).
Obese mice have normal antibody production but impaired
T-cell recall
Given the decreased lymphatic function in obesity, we next
investigated basal immune responses in obese mice. Obese
mice had a normal ability to produce antibody responses (anti-
OVA IgG1 titers) as compared with controls (Supplementary
Figure S3a online; P=NS). In contrast, T cells collected from
obese mice and stimulated ex vivo using OVA produced
signiﬁcantly less IFNγ and IL-4 as compared with controls,
indicating an impairment in T-cell recall (Supplementary Figure
S3b and c online; Po0.01 and Po0.05, respectively). Impaired
T-cell recall in obese mice was conﬁrmed with ex vivo
stimulation with 2,4-dinitrobenzenesulfonic acid after in-vivo
sensitization with 1-ﬂuoro-2,4-dinitrobenzene (DNFB) demon-
strated signiﬁcantly less IFNγ production as compared with
controls (Supplementary Figure S3d online; Po0.05).
Obese mice have increased contact hypersensitivity
On DNFB challenge, obese mice had increased ear erythema,
swelling, ear thickness, and epidermal thickness at days 3
and 8 as compared with controls, indicating a more severe
inﬂammatory response (Figure 2a–c and Supplementary
Figure S4a online; Po0.01 and Po0.05, respectively). Flow
cytometric analysis of ear tissues collected from obese mice
demonstrated increased numbers of activated T cells (CD4+/
CD69+) (Figure 2d). This correlated with analysis of IFNγ
protein levels in ear tissues and serum, which showed
increased tissue and serum levels of IFNγ in obese mice
(Figure 2e and f; Po0.01 for all). Although lean animals had a
3-fold increase in tissue IFNγ levels, obese mice tissues had a
more than 8-fold increase 3 days after DNFB challenge.
Similarly, although lean mice had only a mild increase in
serum IFNγ levels (~30%), we noted an almost 2-fold increase
in serum levels in obese mice.
Flow cytometry of ear tissues was also performed to analyze
T-cell subtypes in lean and obese mice after DNFB challenge.
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These studies demonstrated a nearly 3-fold increase in CD4+
cells, a 7-fold increase in CD8+ cells, a 4-fold increase in
T-regulatory cells (CD4+/CD25+ cells), and a 4-fold increase in
macrophages (CD11b+/F4/80+) (Figure 3a). Histological stain-
ing was performed and showed that obese mice have
signiﬁcantly decreased capillary lymphatic vessel density
(LYVE-1+ vessels) both at 3 days (nearly 2-fold decrease) and
8 days (4-fold decrease) after DNFB challenge (Figure 3b and c;
Po0.01 for both). In addition, obese animals had signiﬁcantly
increased generalized inﬂammation (CD45+ cells) and T-cell
inﬂammatory inﬁltrate (CD3+ cells) at both time points
examined, indicating that these mice had increased peak
inﬂammation and delayed clearance of this response (Figure
3d–g; Po0.05 for all).
Consistent with our studies with isolated T cells, we found
that obese mice also had remarkably increased inﬂammatory
responses to a nonspeciﬁc inﬂammatory stimulus (croton oil),
suggesting that this response is independent of the changes in
immune cell recall. In these experiments, obese mice treated
with croton oil had remarkably increased ear thickness and
ear weight as compared with controls (Supplementary Figure
S5a–c online; Po0.01 for both). In addition, similar to our
ﬁndings with DNFB, we found that obese mice treated with
croton oil had increased generalized inﬂammation (CD45+
cells), CD3+ cell inﬁltration, and decreased lymphatic vessel
density (LYVE-1+) as compared with controls (Supplementary
Figure S6a–f online; Po0.01 for CD45 and CD3, Po0.05 for
LYVE-1). Taken together, our ﬁndings suggest that obesity
results in impaired lymphatic function, increased basal levels
of skin inﬂammation, and increased immune-speciﬁc and
nonspeciﬁc inﬂammatory dermatitis.
rhVEGF-C improves lymphatic function and decreases contact
hypersensitivity
Given that exogenous administration of VEGF-C has been
shown to improve lymphatic function in many models of
lymphatic insufﬁciency and dysfunction, we investigated its
effect on dermatitis in obesity. Control and obese mice were
treated with rhVEGF-C daily, administered subcutaneously in
the base of the ear for 7 days, and then challenged with DNFB
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Figure 1. Obese mice have impaired lymphatic function at baseline. (a) Representative baseline immunoﬂuorescence images of perilipin staining from ear cross-
sections of control (i.e., lean) and obese mice. Bar=50 μm. (b) Body weights of control and obese mice (n=5 each; *Po0.01). (c) Baseline ear thickness
of control and obese mice (n=5 animals per group; *Po0.01). (d) Representative baseline immunoﬂuorescence images of ear cross-sections from control and
obese mice stained for lymphatic vessel endothelium hyaluronan receptor 1 (LYVE-1) (green), CD45 (red), and DAPI (4',6-diamidino-2-phenylindole; blue).
Bar=50 μm. (e) Cell counts of CD45+ cells per high power ﬁeld (HPF) in ear cross-sections of control and obese mice. Cell counts were performed at × 100
magniﬁcation in a minimum of three sections per mouse and four to ﬁve mice per group. (f) Lymphatic vessel density (LYVE-1+ vessels/HPF) in control and obese
mice. (g) Top: Evans blue lymphangiography of ear skin in control and obese mice at baseline. Outlined area represents injection site. Arrows indicate leakage of
dye from lymphatic vessels. Bottom: representative ear whole-mount images of FITC lectin lymphangiography from control and obese mice. Note decreased
lymphatic uptake (yellow arrows) and extra-lymphatic leakage (dotted white line) of FITC lectin from α-smooth muscle actin (α-SMA)+ collecting lymphatics in
obese mice. Bar=50 μm. (h) Top: representative near-infrared (NIR) imaging of lymphatic vessels in the tail and hind limb. Middle: representative graphs for
NIR imaging demonstrating collecting lymphatic vessel contraction (control, blue; obese, red) in the tail and hind limb of control and obese mice. Bottom:
quantiﬁcation of packet frequency in the tail (n= 5–8 mice per group; *Po0.05) and hind limb (n=5–8 mice per group; *Po0.01) of control and obese mice.
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to elicit a contact hypersensitivity response. The rhVEGF-C
injections continued for 3 more days post challenge after
which inﬂammatory responses were analyzed. Evans blue
lymphangiography showed that injection of rhVEGF-C
increased drainage of interstitial ﬂuid to the collecting
lymphatics (white arrows) in both lean and obese mice after
DNFB challenge (Figure 4a). Consistent with this, whole-
mount staining of ears injected with ﬂuorescently conjugated
tomato lectin revealed uptake of tomato lectin into the
collecting lymphatics of the obese mice after rhVEGF-C
injection, suggesting that this intervention increased transport
of interstitial ﬂuid (Figure 4b). This hypothesis is supported by
the ﬁnding that rhVEGF-C injections increased trafﬁcking of
dendritic cell (DC) trafﬁcking from the ear to the cervical
lymph nodes in both lean and obese mice after DNFB
challenge (Figure 4c; Po0.05). Taken together, these ﬁndings
indicate that VEGF-C treatment in the setting of dermatitis
results in improved lymphatic function in both lean and
obese mice.
On the basis of the above ﬁndings, we next investigated
whether improved lymphatic function in obese mice also
decreased dermatitis. Following DNFB challenge, both
control and obese mice treated with rhVEGF-C had decreased
erythema, swelling, and ear thickness as compared with their
respective controls (Figure 5a, b, d and e; Po0.01 for all).
Whole-ear and epidermal thickness measurements in obese
mice showed a normalization of these measures and were
statistically indistinguishable from baseline values recorded in
lean mice with dermatitis.
Treatment of lean and obese mice with rhVEGF-C also
markedly increased capillary lymphatic vessel density
(LYVE-1+ vessels) but did not alter the number of blood vessels
in the ear (Figure 5c and f, and Supplementary Figure S7a–d
online; Po0.01 and P=NS, respectively). In addition, although
we noted a modest increase in vascular VEGF receptor
(VEGFR)-3 expression by ear skin blood capillaries after DNFB
challenge in both lean and obese mice, these effects were not
further accentuated by rhVEGF-C administration, suggesting
that changes in VEGFR-3 expression that occur in this model
are not regulated by VEGF-C (Supplementary Figure S7a–c
online). Similarly, consistent with previous reports, we found
that although macrophages did not express VEGFR-3 at
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Figure 2. Obese mice have increased contact hypersensitivity. (a) Top: representative gross images of control and obese mice ears shown 3 and 8 days after
challenge with 1-ﬂuoro-2,4-dinitrobenzene (DNFB). Bottom: representative histology of ear skin sections of control and obese mice 3 and 8 after challenge
with DNFB. Low-power (×5, bar=100 μm) and high-power (×20, bar= 50 μm). Brackets in high-power images demonstrate epidermal ear thickness.
(b) Quantiﬁcation of ear thickness in control and obese mice 3 and 8 days after DNFB challenge (n=5–8 animals per group; *Po0.01). (c) Quantiﬁcation
of epidermal thickness in control and obese mice 3 and 8 days after DNFB challenge (n=5–8 animals per group; *Po0.01). (d) Representative dot plots
of ear skin ﬂow cytometry at baseline and 3 days after challenge with DNFB analyzing activated T-helper cells (CD3+/CD69+/CD4+). (e) Quantiﬁcation of
ear tissue IFNγ protein concentration in control and obese mice at baseline and 3 days following DNFB challenge (n=5 animals per group *Po0.01).
(f) Quantiﬁcation of serum IFNγ protein concentration in control and obese mice at baseline and 3 days following DNFB challenge (n= 5–8 animals per group;
*Po0.01).
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baseline in either lean or obese mice (data not shown), there
was a modest increase in VEGFR-3 expression 3 days following
DNFB challenge (Supplementary Figure S7e online; upper
panel) (Schoppmann et al., 2002). However, similar to our
ﬁndings with blood vessel expression of VEGFR-3, changes
in macrophage expression of this receptor were not further
modulated by rhVEGF-C administration (Supplementary Figure
S7e online; lower panel).
In addition, immunohistochemical and immunoﬂuorescence
staining of ear tissues demonstrated signiﬁcantly decreased
inﬁltration of F4/80+, CD3+, and CD45+cells in both lean and
obese mice treated with rhVEGF-C as compared with their
respective controls (Figure 5g–i and Supplementary Figure S8a
and b online; Po0.01 for all). Again, similar to our ﬁndings
with ear thickness and epidermal thickness, we found that the
number of these inﬂammatory cells in ear sections of obese
mice normalized back to baseline levels noted in lean mice
with dermatitis. Taken together, rhVEGF-C treatment of obese
mice leads to increased lymphatic vessel density, improved
lymphatic function, and decreased dermatitis as compared
with untreated controls.
rhVEGF-C increases lymphatic endothelial cell expression of
CCL21 and decreases perilymphatic iNOS
To study the cellular mechanisms regulating decreased DC
trafﬁcking and impaired lymphatic pumping capacity in obese
mice, we next analyzed expression of CCL21 using ear whole-
mount immunoﬂuorescence staining (Figure 6a). Consistent
with the known role of CCL21 in regulating DC migration to
lymphatic vessels and our observation that obese animals have
impaired trafﬁcking of DCs, we noted a remarkable decrease in
ear lymphatic CCL21 expression of obese mice as compared
with lean mice at baseline (Figure 6a; upper panel). Similarly,
we found that although contact hypersensitivity increased
lymphatic vessel CCL21 expression in both lean and obese
mice, this increase was blunted in obese mice as compared
with lean controls (Figure 6a; middle panel). Finally, consistent
with the known role of VEGF-C in regulating CCL21 expression
by lymphatic endothelial cells, as well as our observation that
rhVEGF-C increased DC trafﬁcking in obese mice, we noted
that obese mice treated with subcutaneous rhVEGF-C injec-
tions demonstrated remarkable increases in lymphatic CCL21
expression (Figure 6a; lower panel).
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Figure 3. Obesity decreases clearance of contact hypersensitivity–induced inﬂammation. (a) Representative ﬂow plots analyzing control and obese mouse ears
3 days after 1-ﬂuoro-2,4-dinitrobenzene (DNFB) challenge. Top: T-helper (CD3+/CD4+) and cytotoxic T cells (CD3+/CD8+); middle: T-regulatory cells (CD3+/
CD4+/CD25+); bottom: macrophages (CD11b+/F4/80+). Representative immunoﬂuorescence localization (b) and quantiﬁcation (c) of lymphatic vessel
endothelium hyaluronan receptor 1 (LYVE-1)+ vessels (green) in ear skin cross-sections collected from control and obese mice 3 or 8 days following DNFB
challenge (n= 5–6 each; *Po0.01). Blue stain is DAPI (4',6-diamidino-2-phenylindole). Bar=100 μm. Representative immunoﬂuorescence localization (d) and
quantiﬁcation (e) of CD45+ cells (red) and LYVE-1+ vessels (green) in ear skin cross-sections collected from control and obese mice 3 or 8 days following DNFB
challenge (n=5–10 each; *Po0.05). Blue stain is DAPI. Bar=100 μm. Representative immunoﬂuorescence localization (f) and quantiﬁcation (g) of CD3+ cells
(red) and LYVE-1+ vessels (green) in ear skin cross-sections collected from control and obese mice 3 or 8 days following DNFB challenge (n=5–10 each;
*Po0.05). Blue stain is DAPI. Bar=100 μm.
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Previous studies have shown that inﬂammatory cell
expression of inducible nitric oxide synthase (iNOS) in
response to cutaneous inﬂammatory responses decreases
collecting lymphatic pumping capacity (Liao et al., 2011).
Therefore, to determine whether this mechanism contributed to
obesity-induced lymphatic dysfunction and increased cuta-
neous hypersensitivity responses, we localized iNOS expres-
sion by macrophages in ear whole-mount samples (Figure 6b).
Consistent with our ﬁnding that obese mice, at baseline, have
decreased lymphatic vessel pumping, we found that there is a
profound increase in the perilymphatic inﬂammation, and that
the majority of these cells express iNOS (Figure 6b; upper
panel). In addition, lymphatic collectors in obese mice tended
to be more dilated than lean controls (Figure 6b; upper panel).
Three days after the onset of contact hypersensitivity, we noted
a remarkable increase in perilymphatic inﬂammation and
iNOS expression in both control and obese mice; however,
this response was accentuated in obese animals (Figure 6b;
middle panel). Similarly, treatment of both lean and obese mice
decreased perilymphatic iNOS expression, although this
response was less pronounced in obese mice (Figure 6b; lower
panel). Taken together, our results suggest that obesity
decreases lymphatic function by multiple mechanisms includ-
ing generalized decrease in lymphatic vessel density, increased
leakage of initial lymphatics, and decreased collecting vessel
pumping capacity. These effects are modulated, at least in part,
by decreased expression of lymphatic endothelial cell chemo-
tactic molecules and exogenous expression of iNOS by
perilymphatic inﬂammatory cells.
DISCUSSION
Contact dermatitis is a common inﬂammatory skin disease
resulting from T-cell-mediated delayed type hypersensitivity
reactions elicited by skin contact with an irritant in sensitized
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Figure 4. Subcutaneous injection of recombinant human vascular endothelial growth factor (rhVEGF)-C in ear skin improves lymphatic function and decreases
contact hypersensitivity in both lean and obese mice. (a) Evans blue lymphangiography of control and obese mouse ears 3 days after 1-ﬂuoro-2,4-dinitrobenzene
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individuals. The irritant or hapten-laden antigen-presenting
cells from the skin migrate to the draining lymph nodes,
where they present the hapten–peptide–major histocompat-
ibility complexes to T cells, leading to clonal expansion of
speciﬁc memory/effector T cells and subsequent recruitment
to primary sites of skin contact (Vocanson et al., 2005). On re-
exposure, a robust hapten-speciﬁc T-cell-mediated inﬂamma-
tory reaction occurs in the skin (Vocanson et al., 2009).
However, although it is well known that obesity is associated
with increased incidence and severity of atopic and contact
dermatitis, the cellular mechanisms that regulate this effect
remain poorly understood.
In the current study, we show that similar to the clinical
scenario, obese mice exhibit an exaggerated inﬂammatory
response to sensitizing agents (DNFB) and nonspeciﬁc irritants
(croton oil). These responses are characterized by increased
peak inﬂammation and delayed clearance of inﬂammatory cell
inﬁltrates. In addition, we found that obese mice had profound
derangements of their lymphatic system, including decreased
lymphatic vessel density, leaky initial lymphatics, and impaired
collecting lymphatic pumping capacity. As the lymphatics
have a key role in both antigen and inﬂammatory cell removal,
our ﬁndings suggest that obesity-induced lymphatic dysfunc-
tion increases dermatitis responses due to the cumulative
effect of impaired antigen clearance during the elicitation
phase and impaired removal of inﬂammatory cells post
elicitation. This hypothesis is supported by our ﬁnding that
improving lymphangiogenesis and lymphatic function remark-
ably decreases inﬂammatory responses in obese mice. In
addition, our hypothesis is supported by previous studies
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Figure 5. Improving lymphatic function in obese mice with recombinant human vascular endothelial growth factor (rhVEGF)-C decreases contact
hypersensitivity. (a) Representative gross images of control and obese mice 3 days following 1-ﬂuoro-2,4-dinitrobenzene (DNFB) challenge. Mice were treated
with daily ear subcutaneous injections of PBS or rhVEGF-C (7 days before and 3 days after DNFB challenge). Note decreased gross inﬂammatory response in both
lean and obese mice treated with rhVEGF-C. (b) Representative low- and high-power (boxed areas) histological cross-sections of control and obese mouse ears
shown in a. Brackets in high-power images demonstrate epidermal ear thickness. Bar=100 μm (low power) and 50 μm (high power). (c) Representative
immunoﬂuorescence localization of lymphatic vessel endothelium hyaluronan receptor 1 (LYVE-1)+ vessels in ear whole-mount images of control and obese
mouse ears shown in a. Note increased lymphatic vessel density in rhVEGF-C-treated animals. Bar=100 μm. Quantiﬁcation of ear thickness (d) and epidermal
thickness (e) of animal groups described in b (n= 5–8 animals per group; *Po0.01). (f) Lymphatic vessel areas (LYVE-1+ vessels) in control and obese mice treated
with PBS or rhVEGF-C and collected 3 days following DNFB challenge. (g) Representative immunoﬂuorescence localization of macrophages (upper panels;
F4/80+ cells shown in red) and T cells (lower panels; CD3+ cells shown in red) in control and obese mice treated with PBS or rhVEGF-C and collected
3 days following DNFB challenge. Lymphatic vessels (LYVE-1+) are shown in green in both panels. Bar=100 μm. Quantiﬁcation of macrophages (F4/80+ cells/
HPF; h) and T cells (CD3+ cells/HPF; i) in control and obese mice treated with PBS or rhVEGF-C and collected 3 days following DNFB challenge (n= 3 HPF per
animal and 5 animals per group; *Po0.01).
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demonstrating that blockade of VEGFR-3 and impaired
lymphangiogenesis remarkably increases the severity of
acute/chronic inﬂammation in general and in chronic hyper-
sensitivity reactions resulting from DNFB exposure in pulmon-
ary and cutaneous models of acute/chronic inﬂammation
(Kaipainen et al., 1995; Baluk et al., 2005; Kataru et al., 2009;
Huggenberger et al., 2010; Sugaya et al., 2012). Thus, targeted
treatments designed to augment lymphatic function may
represent a novel means of treating inﬂammatory disorders of
the skin.
An interesting ﬁnding of our study was that although obese
mice had mildly decreased T-cell recall responses ex vivo,
they maintained a normal ability to produce antibodies after
vaccination and had exaggerated elicitation responses to
antigen stimulation. These ﬁndings suggest that although
obese mice have impaired lymphatic drainage and trafﬁcking
of antigen-presenting cells to regional lymph nodes, they have
enough capacity to elicit a T-cell response on re-stimulation
with an antigen. Therefore, basal increases in cutaneous
inﬂammation and impaired ability to clear antigen/inﬂamma-
tory cells appear to compensate for mildly impaired T-cell
recall in obese mice. This hypothesis is supported by previous
studies in genetic models of lymphatic dysfunction, demon-
strating that despite decreased lymphatic transport function
and impaired antigen cell trafﬁcking to draining lymph nodes
during the sensitization phase, mice with congenital abnorm-
alities of the lymphatic system are still capable of activating
efﬁcient T-cell responses (Platt et al., 2013).
Previous studies have shown that T cells are crucial
regulators of pathologic responses to obesity, including
metabolic syndrome and cancer (Wu et al., 2007; Nishimura
et al., 2009). For example, depletion studies have shown that
T-cell inﬂammatory responses are necessary for inﬁltration of
macrophages and regulate insulin sensitivity (Nishimura et al.,
2009; Winer et al., 2009). In addition, our lab and others have
shown that T cells exert potent anti-lymphangiogenic effects,
and that functional lymphatics are necessary for clearance of
T-cell inﬂammatory responses (Kataru et al., 2011; Zampell
et al., 2012). Thus, it is possible that obesity-induced T-cell
inﬂammation exerts anti-lymphangiogenic effects resulting in
decreased lymphatic vessel density and impaired removal/
clearance of T-cell inﬂammatory responses in sensitized
individuals.
The microenvironment secondary to HFD may also
contribute to the observed lymphatic dysfunction seen in
obesity. Previous studies have shown that inﬂamed
adipocytes can release adipokines such as IL-6 and tumor
necrosis factor-α, as well as substances such as free fatty acids
that have direct effects on surrounding tissues (Hajer et al.,
2008). Speciﬁcally, stearic acid and palmitic acid have been
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Figure 6. Recombinant human vascular endothelial growth factor (rhVEGF)-C increases lymphatic endothelial cell (LEC) expression of CCL21 and decreases
perilymphatic inducible nitrous oxide synthase (iNOS)+ macrophages. (a) Representative low- and high-power (dashed box shown in upper right inset)
immunoﬂuorescence images of ear whole mounts localizing CCL21 (red) and lymphatic vessels (lymphatic vessel endothelium hyaluronan receptor 1 (LYVE-1)+;
green) in control and obese mice. Top: represents before 1-ﬂuoro-2,4-dinitrobenzene (DNFB) challenge (baseline). Middle: represents 3 days after DNFB
challenge+daily intradermal PBS injections (DNFB+PBS). Bottom: represents 3 days after DNFB challenge+daily intradermal rhVEGF-C injections (DNFB
+rhVEGF-C). PBS and rhVEGF-C injections were administered for 7 days before and 3 days after DNFB challenge. Bar=50 μm. (b) Representative
immunoﬂuorescence images of ear whole mounts localizing iNOS (green), macrophages (CD11b+; red), and lymphatic vessels (podoplanin+; white) in control
and obese animals as described in a. Top: baseline images (i.e., no DNFB, no injections). Middle: 3 days after DNFB challenge with pre/post challenge
subcutaneous PBS injections; bottom: 3 days after DNFB challenge with pre/post challenge subcutaneous rhVEGF-C injections. Bar= 50 μm.
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shown to stimulate the TLR-4 inﬂammatory signaling cascade
associated with obesity (Shi et al., 2006; Suganami et al.,
2007; Davis et al., 2008). Whether or not these path-
ways have a direct effect on lymphatic impairment or
are altered due to local injections of VEGF-C will require
additional study.
Previous studies, in contrast to our ﬁndings, have suggested
that obese mice have impaired contact hypersensitivity
responses as compared with lean mice (Katagiri et al.,
2007). This discrepancy is likely related to technical
differences and varying deﬁnitions of obesity used between
our studies. For example, some studies used only short
periods of HFD exposure (1–2 weeks in one study or as long
as 37 days in another), whereas in our current study,
consistent with previously published reports on diet-induced
obesity in mice, animals were maintained on a HFD for much
longer periods of time (10–12 weeks). As a result, obese mice
in our study were nearly 25 g heavier (or double the body
weight) compared with lean controls. In contrast, the
aforementioned study recorded maximum weight gains of
only 4 g compared with their lean controls. This is important,
as we have found that obesity-induced lymphatic dysfunction
is not typically measurable unless the total body weight is
>45 g (unpublished results). This ﬁnding is supported by
previous clinical studies in overweight patients, suggesting that a
body mass index threshold of 59 is necessary for spontaneous
development of lower extremity lymphedema (Greene et al.,
2012). Thus, direct comparison of our study with previous
reports on obesity and dermatologic inﬂammation is difﬁcult, as
mice treated in the latter studies likely did not meet the weight
threshold to exhibit lymphatic dysfunction.
Consistent with previous studies, we found that delivery
of VEGF-C markedly increased lymphangiogenesis and
improved lymphatic function (Szuba et al., 2002; Yoon
et al., 2003). In addition, we found that VEGF-C injections
increased cutaneous lymphatic endothelial cell expression of
CCL21 and decreased iNOS accumulation around collecting
lymphatic vessels, which provide potential mechanisms for
decreased contact hypersensitivity through improved immune
cell trafﬁcking in both lean and obese mice. Importantly, we
found the effect of VEGF-C to be speciﬁc to the lymphatic
vessels as we did not observe obesity-related differences in
blood vessel counts or changes in VEGFR-3 expression on
blood vessels or macrophages after VEGF-C treatment. The
ﬁnding that VEGF-C injections decrease inﬂammation in
obese animals is consistent with previous studies in lean mice
demonstrating that subcutaneous injection of recombinant
VEGF-C156S protein in K14-VEGF-A transgenic mice (a
model of chronic skin inﬂammation) decreases ear swelling
and inﬂammation (Huggenberger et al., 2010). Other studies
in lean mice using adenoviral transfer of VEGF-C/blockade of
VEGF-R3 with neutralizing antibodies or transgenic over-
expression of VEGF-C in the skin (K14-VEGF-C) have also
shown that the VEGF-C–VEGFR3 signaling pathway has an
important role in the resolution of skin inﬂammation, and that
increased lymphatic density accelerates this process (Kataru
et al., 2009; Hagura et al., 2014). In an interesting clinical
study, Cliff et al. (1999) found that patients with plaque
psoriasis have proliferation of lymphatic vessels surrounding
the plaque but decreased numbers of lymphatic vessels within
the plaque. Furthermore, vessels within the plaque had
impaired lymphatic uptake, suggesting that impaired
lymphatic function may contribute to the pathology of
plaque psoriasis. Taken together, our ﬁndings in the context
of previous reports in the literature support the hypothesis that
dermal lymphatics have a key role in the resolution of
inﬂammatory responses, and that dysfunction of these
networks in obesity promotes exaggerated hypersensitivity
reactions.
MATERIALS AND METHODS
Diet-induced obesity
All experimental protocols were reviewed and approved by the
Institutional Animal Care and Use Committee at Memorial Sloan
Kettering Cancer Center. Six-week-old male C57BL/6J (Jackson
Laboratories, Bar Harbor, ME) mice were fed either a HFD (60% kcal
from fat; W.F Fisher & Son, Somerville, NJ) or a normal chow diet
(13% kcal from fat; Purina PicoLab Rodent Diet 20, W.F. Fisher &
Son) ad libitum for 10–12 weeks (Nishimura et al., 2009; Weitman
et al., 2013). At the conclusion of the experiment, animals were
weighed using a digital scale (Sartorius, Bradford, MA).
Analysis of lymphatic function
Lymphangiography using Evans blue dye (2 μl of 1% (wt/vol)) (Sigma-
Aldrich, St. Louis, MO) was used to identify leaky lymphatic vessels
and analyze lymphatic architecture (Jang et al., 2013). Functional
lymphatic vessel staining was performed by injecting tomato lectin
(1 mgml− 1; Sigma-Aldrich) in the apex of the ear, followed by
euthanization 10minutes later, as described previously (Nishimura
et al., 2009). All experiments were performed with a minimal of ﬁve
animals per group.
NIR imaging was performed using a modiﬁcation of the methods
reported previously (Weiler et al., 2012; Weiler and Dixon, 2013;
Nelson et al., 2014). Brieﬂy, animals were anesthetized with 2%
isoﬂurane and placed on a heating pad after depilation. The ﬁeld of
view was adjusted to capture the entire tail and left hind limb. NIR
probes were made using previously established protocols for
conjugating IRDye 800 CW (LI-COR Biotechnology, Lincoln, NE)
to a 40-kDa polyethylene glycol molecule (JenKem Technology USA,
Allen, TX) (Proulx et al., 2013). A measure of 10 μl of the NIR probe
was injected intradermally at the tip of the tail or in the footpad of the
hind limb. NIR images of dynamic ﬂuorescence transport were
captured for 10minutes at 10 fps and a 50-ms exposure time. Image
processing of the 10minutes image sets were used to determine the
ﬂuorescence packet frequency. Fluorescence intensity within regions
of interest was drawn and tracked using a custom LabVIEW (National
Instruments, Austin, TX) virtual interface. The lymphatic packet
frequency was determined to be the number of distinct ﬂuorescence
packets passing through the regions of interest on the lymphatic
vessels per minute.
The rate of lymphatic ﬂuid transport from peripheral tissues to the
systemic circulation was analyzed using FITC-conjugated dextran
(2,000 kDa, 10 mgml− 1, Invitrogen, Grand Island, NY) injected
bilaterally into the forepaw under controlled pressure followed by
analysis of signal intensity in the serum (IVIS 200 optical imaging
system; Xenogen, Alameda, CA).
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Immunization and T-cell recall
Mice were immunized intradermally in each hind limb (40 μl per
injection) and tail (20 μl) with 0.1 mgml− 1 chicken OVA (Bachem,
Torrance, CA) in a 1:1 emulsion of PBS and alum (Thermo Scientiﬁc,
Waltham, MA) followed by a booster 10 days later as described
previously (Thomas et al., 2012). Antibody titers in the serum
were analyzed 21 days after immunization using an ELISA (Alpha
Diagnostic International, San Antonio, TX). In addition, the
draining lymph nodes (popliteal, sciatic, and sacral) and the
spleen were collected and digested to form cell suspensions,
plated, and then stimulated with 5mgml− 1 OVA (Bachem;
dissolved in RPMI). Five days later, cell supernatants were
collected, and IFN-γ and IL-4 cytokine production was analyzed by
ELISA (eBioscience, San Diego, CA), according to the manufacturer’s
protocol.
T-cell recall was performed similarly with 2,4-dinitrobenzenesul-
fonic. Brieﬂy, DNFB (25 μl of 0.5% DNFB solution; Toronto Research
Chemicals, Toronto, Ontario) was mixed in acetone with 20% olive
oil and painted onto the shaved abdomens of mice. Five days later,
spleens and draining lymph nodes were collected. T cells were
isolated from the spleens and lymph nodes using positive selection
CD3 magnetic beads (Miltenyi Biotec, Cambridge, MA) as per the
manufacturer’s recommendations, and were subsequently plated and
then stimulated with 50 μM 2,4-dinitrobenzenesulfonic (Sigma-
Aldrich) for 5 days after which conditioned medium was collected
and IFN-γ cytokine production was analyzed by ELISA (eBioscience),
according to the manufacturer’s protocol.
Model of contact hypersensitivity
To establish contact hypersensitivity, we used a modiﬁed previously
described technique (Martin-Romero et al., 2000). Twenty-ﬁve
microliters of 0.5% DNFB (Toronto Research Chemicals) in acetone
with 20% olive oil was painted onto the shaved abdomens of mice.
Five days later, one ear was challenged with 0.3% DNFB.
Histological ear swelling was measured at 3 and 8 days post
challenge.
Model of nonspeciﬁc inﬂammation
To determine whether obese mice had prolonged resolution and
clearance of nonspeciﬁc inﬂammation, we used a well-described
croton oil assay (Sugaya et al., 2012). Twenty microliters of 2%
croton oil (Sigma-Aldrich) dissolved in 70% acetone (Fisher
Scientiﬁc, Pittsburgh, PA) was painted onto the inner ear surface
followed by analysis 18 hours later.
rhVEGF-C therapy and DC trafﬁcking
One microliter of rhVEGF-C (0.1mgml−1, R&D, Minneapolis, MN)
was injected intradermally with a Hamilton syringe into the base of the
ear in obese and lean animals every day for 7 days before induction of
contact hypersensitivity and for 3 days post challenge for a total of
10 days (Szuba et al., 2002). Control animals were injected with 1 μl of
sterile PBS. To quantify DC trafﬁcking, we used a modiﬁcation of
previously reported methods (Lim et al., 2009). Brieﬂy, the spleens of
CD45.1 B6.SJL-Ptprca Pepcb/BoyJ mice (Jackson Laboratories) were
collected and digested with collagenase D (Sigma-Aldrich). CD45.1+
DCs were enriched using a magnetic microbead-based positive
selection kit for CD11c+ cells (Miltenyi Biotec, Gladbach, Germany).
Isolated cells were resuspended in PBS and injected into the apex of
the right ear (106 cells per injection), and 18 hours later the right
cervical lymph nodes were collected and analyzed for migrating
DCs (CD45.1+/CD11c+/MHC-IIhigh) using ﬂow cytometry (LSRII; BD
Biosciences, San Jose, CA) and FlowJo software (Tree Star, Ashland,
OR). Each experiment was repeated with four to ﬁve animals
per group.
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